ANDA 209787, held by Lotus Pharmaceutical. Methotrexate Sodium.
As of Nov 21, 2026, ANDA 209787 (Methotrexate Sodium), held by Lotus Pharmaceutical, was first approved by FDA on Apr 23, 2021, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 23, 2021 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Methotrexate SodiumEQ 2.5MG BASE · tablet;oral | Methotrexate Sodium | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters